EP2906201A4 - Forme de dosage solide - Google Patents

Forme de dosage solide

Info

Publication number
EP2906201A4
EP2906201A4 EP13845400.4A EP13845400A EP2906201A4 EP 2906201 A4 EP2906201 A4 EP 2906201A4 EP 13845400 A EP13845400 A EP 13845400A EP 2906201 A4 EP2906201 A4 EP 2906201A4
Authority
EP
European Patent Office
Prior art keywords
dosing form
solid dosing
solid
dosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13845400.4A
Other languages
German (de)
English (en)
Other versions
EP2906201A1 (fr
Inventor
Chin Beng Stephen Lim
Vivian Bruce Sunderland
Yip Hang Eddy Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IX Biopharma Ltd
Original Assignee
IX Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012238330A external-priority patent/AU2012238330B1/en
Application filed by IX Biopharma Ltd filed Critical IX Biopharma Ltd
Publication of EP2906201A1 publication Critical patent/EP2906201A1/fr
Publication of EP2906201A4 publication Critical patent/EP2906201A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP13845400.4A 2012-10-11 2013-10-11 Forme de dosage solide Withdrawn EP2906201A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2012238330A AU2012238330B1 (en) 2010-10-26 2012-10-11 Fast Dissolving Solid Dosage Form
AU2013200684A AU2013200684B1 (en) 2010-10-26 2013-02-08 Fast Dissolving Solid Dosage Form
AU2013200682A AU2013200682C1 (en) 2010-10-26 2013-02-08 Fast Dissolving Solid Dosage Form
PCT/IB2013/002594 WO2014057351A1 (fr) 2012-10-11 2013-10-11 Forme de dosage solide

Publications (2)

Publication Number Publication Date
EP2906201A1 EP2906201A1 (fr) 2015-08-19
EP2906201A4 true EP2906201A4 (fr) 2016-10-19

Family

ID=50478109

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13845400.4A Withdrawn EP2906201A4 (fr) 2012-10-11 2013-10-11 Forme de dosage solide

Country Status (11)

Country Link
EP (1) EP2906201A4 (fr)
JP (1) JP2015533155A (fr)
KR (1) KR20150063567A (fr)
CN (2) CN107669649A (fr)
CA (1) CA2886573C (fr)
HK (1) HK1208353A1 (fr)
IL (2) IL238104B (fr)
MY (1) MY191875A (fr)
NZ (1) NZ706302A (fr)
SG (1) SG11201502425WA (fr)
WO (1) WO2014057351A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6217052B2 (ja) * 2016-04-21 2017-10-25 邦赫 小牧 口腔清浄用発泡性錠剤
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
WO2017192921A1 (fr) 2016-05-05 2017-11-09 Monosol Rx, Llc Compositions d'épinéphrine à administration améliorée
JP2017193547A (ja) * 2017-05-08 2017-10-26 邦赫 小牧 口腔清浄用発泡性錠剤
KR20200060748A (ko) * 2017-09-27 2020-06-01 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 및 프로드러그 조성물
EP3687509A1 (fr) * 2017-09-27 2020-08-05 Aquestive Therapeutics, Inc. Compositions pharmaceutiques à perméation améliorée
IT201800003507A1 (it) * 2018-03-13 2019-09-13 Fulton Medicinali S P A Compressa sublinguale comprendente sildenafil citrato
SMT202600055T1 (it) * 2019-01-07 2026-03-09 Antecip Bioventures Ii Llc Combinazione di destrometorfano e bupropione per trattare la depressione in pazienti asiatici
CN109846841B (zh) * 2019-01-18 2021-06-01 西安力邦医药科技有限责任公司 一种速效氯巴占口服冻干制剂及其制备方法
US12589083B2 (en) * 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11382873B1 (en) * 2021-01-08 2022-07-12 Vitalis Analgesics LLC Oral administration of ketamine
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
WO2025120580A1 (fr) * 2023-12-08 2025-06-12 Ix Biopharma Ltd Compositions et méthodes pour induire une réponse immunitaire mucosale

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005820A1 (fr) * 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Dispersions solides de citrate de sildenafil ayant une forte solubilite dans l'eau
US7407669B2 (en) * 1998-09-25 2008-08-05 Mcneil-Ppc, Inc. Fast dissolving orally consumable films
US20090246257A1 (en) * 2008-03-27 2009-10-01 Pankaj Modi Wafer formulation
US20100240724A1 (en) * 2007-10-03 2010-09-23 C.L. Pharm Edible Film
US20110009834A1 (en) * 2008-03-15 2011-01-13 Lts Lohmann Therapie-Systeme Ag Gingival wafer
WO2011117313A1 (fr) * 2010-03-23 2011-09-29 Bioalliance Pharma Systèmes d'administration de médicaments à dissolution rapide
CN102438596A (zh) * 2008-11-03 2012-05-02 尼克美制药有限公司 置入口腔的剂型
FR2967066A1 (fr) * 2010-11-04 2012-05-11 Ethypharm Sa Utilisation par voie sublinguale de microgranules non comprimes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
EP2343045A3 (fr) * 2003-02-24 2011-09-21 Pharmaceutical Productions Inc. Système d'administration de médicament par voie transmucosique
CA2612917A1 (fr) * 2005-06-23 2007-01-04 Schering Corporation Formulations orales a absorption rapide d'inhibiteurs de la pde5
WO2009045022A2 (fr) * 2007-10-03 2009-04-09 C.L. Pharm Film comestible
DK2493457T3 (en) * 2009-10-30 2017-10-02 Ix Biopharma Ltd QUICK-SOLVING SOLID DOSAGE FORM
JP5841433B2 (ja) * 2012-01-11 2016-01-13 日東電工株式会社 口腔内フィルム状基剤及び製剤
AU2014233363B2 (en) * 2013-03-15 2017-06-29 EyePoint, Inc. Compositions, formulations and methods for treating ocular diseases

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407669B2 (en) * 1998-09-25 2008-08-05 Mcneil-Ppc, Inc. Fast dissolving orally consumable films
WO2002005820A1 (fr) * 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Dispersions solides de citrate de sildenafil ayant une forte solubilite dans l'eau
US20100240724A1 (en) * 2007-10-03 2010-09-23 C.L. Pharm Edible Film
US20110009834A1 (en) * 2008-03-15 2011-01-13 Lts Lohmann Therapie-Systeme Ag Gingival wafer
US20090246257A1 (en) * 2008-03-27 2009-10-01 Pankaj Modi Wafer formulation
CN102438596A (zh) * 2008-11-03 2012-05-02 尼克美制药有限公司 置入口腔的剂型
WO2011117313A1 (fr) * 2010-03-23 2011-09-29 Bioalliance Pharma Systèmes d'administration de médicaments à dissolution rapide
FR2967066A1 (fr) * 2010-11-04 2012-05-11 Ethypharm Sa Utilisation par voie sublinguale de microgranules non comprimes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHONG CHUI ET AL: "Development of a Sublingual/Oral Formulation of Ketamine for Use in Neuropathic Pain Preliminary Findings from a Three-Way Randomized, Crossover Study", CLINICAL DRUG INVESTIGATION, vol. 29, no. 5, 2009, pages 317 - 324, XP009191103, ISSN: 1173-2563 *
DEVECI S ET AL: "SUBLINGUAL SILDENAFIL IN THE TREATMENT OF ERECTILE DYSFUNCTION: FASTER ONSET OF ACTION WITH LESS DOSE", INTERNATIONAL JOURNAL OF UROLOGY, CHURCHILL LIVINGSTONE, TOKYO, JP, vol. 11, no. 11, 1 January 2004 (2004-01-01), pages 989 - 992, XP008068622, ISSN: 0919-8172, DOI: 10.1111/J.1442-2042.2004.00933.X *
DIXIT R P ET AL: "Oral strip technology: Overview and future potential", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 139, no. 2, 15 October 2009 (2009-10-15), pages 94 - 107, XP026601268, ISSN: 0168-3659, [retrieved on 20090624], DOI: 10.1016/J.JCONREL.2009.06.014 *
JOSHUA S BOATENG ET AL: "Characterisation of freeze-dried wafers and solvent evaporated films as potential drug delivery systems to mucosal surfaces", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 389, no. 1, 9 January 2010 (2010-01-09), pages 24 - 31, XP028308317, ISSN: 0378-5173, [retrieved on 20100118], DOI: 10.1016/J.IJPHARM.2010.01.008 *
SANFORD M: "Vardenafil orodispersible tablet", DRUGS, ADIS INTERNATIONAL LTD, NZ, vol. 72, no. 1, 1 January 2012 (2012-01-01), pages 87 - 98, XP009189559, ISSN: 0012-6667, DOI: 10.2165/11208270-000000000-00000 *
SUBASHVIJAYAKUMAR ET AL: "OVERVIEWONFASTDISSOLVINGFILMS", 3 May 2010 (2010-05-03), XP055291076, Retrieved from the Internet <URL:http://www.ijppsjournal.com/Vol2Suppl3/665.pdf> [retrieved on 20160725] *
TOURDOT S ET AL: "The use of a mucoadhesive microparticulate delivery system enables allergen dose reduction with equivalent efficacy in sublingual immunotherapy", ALLERGY, WILEY-BLACKWELL PUBLISHING LTD, UNITED KINGDOM, vol. 66, no. Suppl. 94, 1 June 2011 (2011-06-01), pages 135, XP009189546, ISSN: 0105-4538 *

Also Published As

Publication number Publication date
KR20150063567A (ko) 2015-06-09
IL273076A (en) 2020-04-30
MY191875A (en) 2022-07-18
IL238104B (en) 2020-03-31
EP2906201A1 (fr) 2015-08-19
SG11201502425WA (en) 2015-05-28
IL238104A0 (en) 2015-05-31
WO2014057351A1 (fr) 2014-04-17
CN107669649A (zh) 2018-02-09
CN104812378A (zh) 2015-07-29
CN104812378B (zh) 2017-12-01
CA2886573C (fr) 2019-04-02
JP2015533155A (ja) 2015-11-19
CA2886573A1 (fr) 2014-04-17
HK1208353A1 (en) 2016-03-04
NZ706302A (en) 2017-07-28

Similar Documents

Publication Publication Date Title
EP2906201A4 (fr) Forme de dosage solide
CO7010838A2 (es) Compuestos de imidazopirrolidinona
DK3181122T3 (da) Farmaceutisk dasatinib-sammensætning
PL2919766T3 (pl) Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
DK2694038T3 (da) Farmaceutisk sammensætning
PT3725778T (pt) Formulações de enzalutamida
EP2869371A4 (fr) Mélange pour électrode positive
DK3677252T3 (da) Doseringsregimer for echinocandin-klasse forbindelser
PT3068786T (pt) Compostos de pirazolopirimidina
PT2854768T (pt) Composições farmacêuticas de pemetrexed
ZA201501928B (en) Pharmaceutical antiretroviral composition
EP2913286A4 (fr) Distributeur doseur
EP2877280A4 (fr) Matières de catalyseur
DK2897594T3 (da) Farmaceutisk sammensætning
BR112015003116A2 (pt) preparação farmacêutica sólida contendo levotiroxina
ES2721400T8 (es) Composición de Diclofenaco
DK2815752T3 (da) Oral farmaceutisk sammensætning
ES1078291Y (es) Tapón dosificador Bi-flujo
EP2838488A4 (fr) Distributeurs de médicaments
EP2990038A4 (fr) Composition pharmaceutique solide
EP2825475A4 (fr) Buse
EP2815753A4 (fr) Composition pharmaceutique orale
EP2769718A4 (fr) Composition médicinale
DOS2012000293S (es) Sarten
EP2883547A4 (fr) Médicament

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150428

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1208353

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/26 20060101AFI20160503BHEP

Ipc: A61K 9/20 20060101ALI20160503BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160916

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/26 20060101AFI20160912BHEP

Ipc: A61K 9/20 20060101ALI20160912BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IX BIOPHARMA LTD

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20171120

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180404

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1208353

Country of ref document: HK